Previous 10 | Next 10 |
Coeptis Therapeutics Announces Intent to Acquire TLR5 Agonist Platform, Including Clinical-Stage Asset Entolimod, from Statera Biopharma PR Newswire Entolimod is currently in clinical development as a potential treatment for acute radiation syndrome with additional pre...
FORT COLLINS, Colo., March 31, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostas...
Live Conference Call and Webcast at 5:30 p.m. ET FORT COLLINS, Colo., March 28, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immu...
FORT COLLINS, Colo., March 24, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostas...
Statera Biopharma (NASDAQ: STAB) , a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced the pricing of its underwritten public offering. The offering is comprised of an estimated 10,843,721 units, offered t...
Statera Biopharma (STAB -39.0%) shares are down after the biopharmaceutical company announced pricing of a ~$5.7M stock offering. The offering comprises ~10.84 units, issued at $0.45/unit, and ~1.72M pre-funded units, offered at $0.44/pre-funded unit. Each unit consists of one share of common...
FORT COLLINS, Colo., March 22, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, ...
FORT COLLINS, Colo., March 22, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostas...
Statera Biopharma (NASDAQ:STAB) said it has started public stock offering while the actual size and other terms remain undisclosed. The offering of units will comprise of one common share and one warrant to purchase additional share each, and pre-funded units. EF Hutton, division of Benchmark...
FORT COLLINS, Colo., March 21, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostas...
News, Short Squeeze, Breakout and More Instantly...
Statera Biopharma Inc. Company Name:
STAB Stock Symbol:
NASDAQ Market:
Statera Biopharma Inc. Website:
Williams Industrial Services Group Inc. (WLMSQ) is expected to report $-0.15 for Q3 2023 Cellcom Israel Limited (CELJF) is expected to report for quarter end 2023-09-30 Central Japan Railway Co ADR (CJPRY) is expected to report for Q2 2024 CW Petroleum Corp (CWPE) is expected to repor...
Strategic Environmental & Energy Resources Inc (SENR) is expected to report for Q1 2024 Biocept Inc. (BIOCQ) is expected to report for Q1 2024 Kalera Public Limited Company (KALRQ) is expected to report for quarter end 2023-09-30 Lanvin Group Holdings Limited (LANV) is expected to...
Murata Manufacturing Co. Ltd. ADR (MRAAY) is expected to report $0.27 for Q2 2024 Quotient Limited (QTNTQ) is expected to report for quarter end 2023-09-30 Evaxion Biotech A/S (EVAX) is expected to report for Q3 2023 American Virtual Cloud Technologies Inc. (AVCTQ) is expected to repo...